A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer

Study Overview

The purpose of this study is to estimate the pathological complete response rate at the time of surgery in patients with stage IIIA (N2) NSCLC treated with concurrent Carboplatin/Paclitaxel/Durvalumab plus radiation therapy followed by surgical resection followed by adjuvant Durvalumab.

Study Description

We are doing this study to find out if the combination of chemotherapy, radiation and FDA approved Durvalumab, followed by surgical resection of your cancer is safe and if it will keep your disease away for a longer period of time.  We are also looking at whether adding Durvalumab maintenance after surgical reseaction will provide a longer period of time that your cancer is inactive.

  • IRB Number: 1902410868 (LUN17-321)
  • Research Study Identifier: TX10373
  • Principal Investigator: Greg Durm, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.